PFE Jan 2023 35.000 call
- Editor's PickYahoo Finance Video
Axios sells itself to Cox Enterprises, Carlyle CEO to step down, CVS and Pfizer look to expand
Yahoo Finance's Julie Hyman breaks down leading business headlines today regarding M&A activity and leadership changes.
- Reuters
UPDATE 1-EU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot
The European Medicines Agency (EMA) has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, it said on Tuesday. The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID - the original strain first identified in China, and the Omicron offshoots BA.4/5 that are currently behind most cases in Europe. A rolling review means the EMA assesses the data as it becomes available, and the process continues until there is enough data for a formal marketing application.
- Business Wire
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
